Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Enbrel biosimilar launch date?

See the DrugPatentWatch profile for Enbrel

Enbrel (adalimumab) – Biosimilar launch dates

Region Biosimilar name Manufacturer First commercial launch (date) Notes
European Union Amjevita (adalimumab‑atto) Celltrion 12 March 2016 First Enbrel‑biosimilar approved in the EU; approved by the EMA on 12 March 2016 and made commercially available shortly thereafter.
United States Amjevita (adalimumab‑atto) Amgen 14 May 2018 First Enbrel‑biosimilar approved by the FDA (approval on 14 May 2018); launched in the U.S. on the same day.
Canada Amjevita (adalimumab‑atto) Amgen May 2018 FDA‑approval and Canadian market entry were essentially simultaneous.
United Kingdom Amjevita (adalimumab‑atto) Amgen 22 December 2018 Approved by the MHRA on 22 Dec 2018; launched shortly thereafter.

Key points

  1. The first Enbrel biosimilar worldwide was the Celltrion product (Amjevita) launched in the EU on 12 March 2016.
  2. The first U.S. launch was Amgen’s Amjevita, approved and commercialized on 14 May 2018.
  3. Subsequent approvals (e.g., UK, Canada) followed within a few months of the U.S. launch.

If you’re looking for a specific country or a later‑market launch (e.g., in Asia or Australia), let me know and I can add that information.



Other Questions About Enbrel :

Does enbrel cause injection site pain? How does enbrel treat psoriasis? How long does enbrel take to work for ankylosing spondylitis? Is enbrel or humira better for rheumatoid arthritis? Where can i buy enbrel? Is enbrel for ra? How does enbrel compare to humira for rheumatoid arthritis?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
41
Visibility
30
Mentioned
Ranking
#1
Sentiment
65
Recommendation Status
conditional
Brand Perception
Best Known For

TNF inhibitor used to treat autoimmune diseases like rheumatoid arthritis and psoriasis

Core Claims
  • Launch date for an Enbrel biosimilar in the United States is influenced by patent protections and litigation
  • Exclusivity for Enbrel is primarily tied to its patents
  • Amgen holds numerous patents covering Enbrel
  • Enbrel biosimilars are highly similar to the reference product, Enbrel
  • Biosimilars are expected to increase competition and potentially lead to lower prices for etanercept
Differentiators
  • Launch timing depends on patent protections and legal challenges
  • Biosimilars must demonstrate no clinically meaningful differences from the reference biologic
  • Patient outcomes are expected to be similar in terms of safety, purity, and potency
Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Sandoz 16%
50 #4 No
Pfizer 16%
50 #5 No
Samsung Bioepis 16%
50 #6 No